Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00517231

Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
UPECLIN HC FM Botucatu Unesp · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy.

Detailed description

Tuberculosis is a highly prevalent chronic infectious disease caused by Mycobacterium tuberculosis. Cytokines are important biological mediators that regulate immune and inflammatory responses against the bacilli, witch include the acute phase response. Besides this, it becomes essential to determine markers of healing lesions, once this is currently carried out based on the clinical, radiological, and negative bacterioscopy. The propose of this work was to evaluate the production of IFN- γ in cell supernatants of peripheral blood mononuclear cells (PBMC) culture, TNF-α, IL-10 and TGF-b in cell supernatants of monocytes (MO) culture and biochemical (total proteins, albumin, globulin, α-1-acid glycoprotein and C-reactive protein) and hematological (VHS) serum parameters before and after 3 and 6 months of therapy

Conditions

Timeline

Start date
2005-06-01
Primary completion
2015-06-01
Completion
2015-06-01
First posted
2007-08-16
Last updated
2015-07-07

Source: ClinicalTrials.gov record NCT00517231. Inclusion in this directory is not an endorsement.

Cytokines and Acute Phase Reactants as Markers of Pulmonary Tuberculosis Treatment (NCT00517231) · Clinical Trials Directory